Increased frequency and suppressive activity of CD127low/− regulatory T cells in the peripheral circulation of patients with head and neck squamous cell carcinoma are associated with advanced stage and nodal involvement

The presence of regulatory T (Treg) cells is thought to be an important mechanism by which head and neck squamous cell carcinoma (HNSCC) successfully evades the immune system. Using multicolour flow cytometry, the frequency and functional capacity of two CD4+ CD127low/− Treg cell populations, separated on the basis of different levels of CD25 expression (CD25inter and CD25high), from the peripheral circulation of newly presenting HNSCC patients were assessed with regard to clinicopathological features and healthy controls. The frequency of circulating Treg cells was similar between HNSCC patients and healthy controls, and for patients with HNSCC developing from different subsites (laryngeal compared with oropharyngeal). However, patients with advanced stage tumours and those with nodal involvement had significantly elevated levels of CD4+ CD25high CD127low/− Treg cells compared with patients who had early stage tumours (P = 0·03) and those without nodal involvement (P = 0·03), respectively. CD4+ CD25high CD127low/− Treg cells from the entire HNSCC patient cohort and from patients whose tumours had metastasized to the lymph nodes were also shown to suppress the proliferation of effector T cells significantly more, compared with those from healthy controls (P = 0·04) or patients with no nodal involvement (P = 0·04). Additionally, CD4+ CD25inter CD127low/− Treg cells consistently induced greater suppressive activity than CD4+ CD25high CD127low/− Treg cells on the proliferation of the effector T‐cell populations (CD4+ CD25− CD127−/+ and CD4+ CD25+ CD127+). Peripheral Treg cells, identified by the CD127low/− phenotype, have been shown to be influenced by a patient's tumour stage and/or nodal status in HNSCC; suggesting a role in tumour progression that could be manipulated by future immunotherapy.

[1]  P. Krammer,et al.  Molecular Mechanisms of Treg-Mediated T Cell Suppression , 2012, Front. Immun..

[2]  Yi-xiang Han,et al.  Elevated frequencies of CD4+CD25+CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia , 2011, International journal of cancer.

[3]  D. Long,et al.  Increased Frequency of CD4+CD25highFoxP3+ Regulatory T Cells in Patients with Hepatocellular Carcinoma , 2011, Archivum Immunologiae et Therapiae Experimentalis.

[4]  M. Carini,et al.  Frequency of regulatory T cells in peripheral blood and in tumour‐infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma , 2011, BJU international.

[5]  P. Delvenne,et al.  Immune Suppression in Head and Neck Cancers: A Review , 2011, Clinical & developmental immunology.

[6]  S. Lang,et al.  Toll-like Receptors in Regulatory T Cells of Patients With Head and Neck Cancer. , 2010, Archives of otolaryngology--head & neck surgery.

[7]  G. Li,et al.  Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma , 2010, Clinical and experimental immunology.

[8]  J. Greenman,et al.  Serum IL10 and circulating CD4+CD25high regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma , 2010, Head & neck.

[9]  B. Wollenberg,et al.  Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. , 2010, International journal of molecular medicine.

[10]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[11]  G. Garlet,et al.  Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment , 2010, Cancer Immunology, Immunotherapy.

[12]  Ti Zhang,et al.  Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma , 2010, Journal of Cancer Research and Clinical Oncology.

[13]  T. Whiteside,et al.  Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. , 2009, Journal of immunological methods.

[14]  E. Shevach Mechanisms of foxp3+ T regulatory cell-mediated suppression. , 2009, Immunity.

[15]  M. Hashibe,et al.  Recent changes in the epidemiology of head and neck cancer , 2009, Current opinion in oncology.

[16]  Dakang Xu,et al.  CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. , 2009, Clinical immunology.

[17]  M. Chovanec,et al.  Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck , 2009, Journal of cellular and molecular medicine.

[18]  H. Fujii,et al.  CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer , 2008, International journal of cancer.

[19]  J. Schlom,et al.  Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer , 2008, Clinical Cancer Research.

[20]  T. Whiteside,et al.  The Frequency and Suppressor Function of CD4+CD25highFoxp3+ T Cells in the Circulation of Patients with Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.

[21]  T. Whiteside,et al.  Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck , 2007, Head & neck.

[22]  J. McCune,et al.  Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. , 2007, Journal of immunological methods.

[23]  J. Woo,et al.  Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patients , 2007, British Journal of Cancer.

[24]  W. Selby,et al.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.

[25]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[26]  S. Kim-Schulze,et al.  Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[28]  T. Whiteside,et al.  Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer , 2005, British Journal of Cancer.

[29]  S. Sakaguchi,et al.  CD4+ Tregs and immune control. , 2004, The Journal of clinical investigation.

[30]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[31]  T. Whiteside,et al.  Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  T. Whiteside,et al.  Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  G. Freeman,et al.  CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.

[34]  M. Roncarolo,et al.  Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.

[35]  D. Sidransky,et al.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.

[36]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[37]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[38]  T. Ye,et al.  Expression of CD4+CD25highCD127low/− regulatory T cells in transitional cell carcinoma patients and its significance , 2009, Journal of clinical laboratory analysis.

[39]  J. Schlom,et al.  Enhanced Functionality of CD 4 + CD 25 highFoxP 3 + RegulatoryTCells in the Peripheral Blood of Patients with Prostate Cancer , 2008 .

[40]  水上 佳樹 CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3[+] regulatory T cells in gastric cancer , 2008 .

[41]  Maura L Gillison,et al.  BASIC SCIENCE REVIEW , 2006 .

[42]  Ray H. Baughman,et al.  Supporting Online Material , 2003 .

[43]  G. Freeman,et al.  CD4CD25 Regulatory Cells in Human Peripheral Blood , 2001 .